Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
-
-
- Triggering Signals of BRCA1 Breast Cancer (K Kessenbrock)
- Testing Diverse Groups Finds New Breast Cancer Genes (L Teras)
- Black Women & Genetic Testing (J Palmer)
- Women 65+ & Genetic Tests for Breast Cancer Risk (L Teras)
- High-Risk Genes and Screening (A Patel)
- New Risk Calculation May Affect Breast Cancer Screening (L Teras)
- Black Men and Breast Cancer (H Sung)
-
- Platelets May Help Breast Cancer Spread (E Battinelli)
- Natural Killer Cells & TNBC (R. Chakrabarti)
- 3D Mini Breast Tumors (K Varley)
- Improving Chemotherapy (O Sahin)
- Combo Treatment for TNBC (K Varley)
- Treatments Attack Cell Division (A Holland)
- ER+ Treatment in Mice (P Kenny)
- Blood DNA Monitors Metastasis Treatment (H P Ji)
- PTK6 Gene as Treatment Target (H Irie)
- Time-Lapse Cell Movies (S Spencer)
-
-
- Better Survival Requires Better Insurance (J Zhao)
- Cancer Disparities in the US (F. Islami)
- Medicaid Eligibility Limits (J Zhao)
- Clinical Trial Treatment Cost App (L Hamel)
- Exercise & Sitting Time (E. Rees-Punia)
- Podcasts, TheoryLab
- Cancer Information about LGBTQ People (B. Charlton)
- Patients Health Insurance Tool (M. Politi)
- Housing Assistance and Mammograms (H Lee)
- Breast Cancer Treatment in Ethiopia (A. Jemal)
- Predicting the Effects of Liver Cancer (C. Wray)
- Disparities' Effect on Cancer Recurrence (M. Hassett)
-
- New Treatment for Neuroblastoma (A Heczey)
- Oncogenic Fusions AML (S Meshinchi)
- Medicare Expansion Improves Survival (X Han)
- Dobbs v Jackson: What to Know (X Han)
- Genetic Risks (L Teras)
- New Medulloblastoma Drugs (J Rodriguez-Blanco)
- Potential New Hope for MLL (J Grembecka)
- Increase in Brain Tumor Diagnosis (K Miller)
- Longer Life Expectancy for Survivors (J Yeh)
- Potential Target for New Osteosarcoma Drugs (C Benavente)
- At-Home Chemo for Children with HR ALL (L Ranney)
- Childhood Cancer Research Landscape Report
-
-
- Tumor-Infiltrating Neutrophils (R. Sumagin)
- New Epigenetic Target (K Rai)
- Extra Chromosomes (Aneuploidy) Effect on Cancer (J. Sheltzer)
- Discovery of a New Biomarker Is the First Step to New Treatment (C. Maher)
- Designer Virus Targets and Kills CRC Cells in Mice (S. Warner)
- Tiny Sensor in Mice May Find Cancer That's Trying to Spread (L. Hao)
- Targeting a Protein “Turned on” by Mistake (N. Gao)
- Spatial Map Intestines (J Hickey)
- CRC Treatment Podcasts
-
- Keto Molecule & Colorectal Cancer (M Levy)
- Availability of Healthy Food (L Tussing-Humphreys)
- 45 Min/Day of Physical Activity (A Minihan)
- Fewer than 10K Steps/Day (A Patel)
- Yogurt & Cheese & ER- Breast Cancer (M McCullough)
- Stage 2 Clinical Trials for New Endometrial Cancer Drug (V Bae-Jump)
- Hard-to-Starve Pancreatic Cancer Cells (N Kalaany)
- Coffee Risks for Colorectal Cancer (C Um)
- Food Parasite & Brain Cancer Risk (J Hodge)
- Exercise & Quality of Life in Older Survivors (E Rees-Punia)
- 21 Metabolites Linked with Breast Cancer (Y Wang)
- Replacing Sitting May Affect Weight (E Rees-Punia)
- CPS-3 Researchers Ask What People Eat and Check Urine Samples (Y Wang)
- Video Games Motivate Exercise? (E. Lyons)
- Food Choices and Colon Cancer Risk (P. Chandler)
- Race, Exercise & Breast Cancer (C. Dallal)
- Diet with Colorectal Cancer (M. Guinter)
-
- Biomarkers May Improve Prediction (Y Wang)
- Kickstart NSCLCs Clinical Trials (L. Eichner)
- Mapping Mitochondria's “Dance” (D. Shackleford)
- E-Cig Use Ages 18 to 29 (P. Bandi)
- Stopping Smoking Earlier in Life (F Islami)
- Most with Lung Cancer Smoked (A Jemal)
- Furthering Lung Cancer Screening & Equity (S Fedewa)
- Mouse Lung Organoids for Research (C Kim)
- Quality of Life for Lung Cancer Survivors (J Temel)
- Precision Therapies for NSCLC (P Jänne)
- Cancer Deaths from Smoking (F Islami)
- Lung Cancer Surgery Disparities (A Jemal)
- BRG1-Deficient Lung Cancers (C Kim)
- Yoga for Couples with Lung Cancer (K Milbury)
- Metabolic Differences as New Drug Targets (A Marcus)
-
- CPS-II & CPS-3 Inform About Risks of Ovarian Cancer
- Machine Learning & Glowing Nanosensors (D Heller)
- Ovarian Cancer May Start in Fallopian Tube Cells (K Lawrenson)
- New Gene Linked with Deadliest Type (C Han)
- Gene-Testing Tools May Personalize Care (A Sood)
- Chromosome-Hoarding Ovarian Cancer Cells & Treatment (J Sheltzer)
- Nanoparticles as Drug Delivery for Metastases (X Lu)
- Turning Off 2 Proteins to Slow HGSC (P Kreeger)
- Targeted Light Therapy in Mice (M Bai)
- Nanoparticles, CAR T, and CRISPR (M Stephan)
- Endometriosis & Ovarian Cancer in Mice (M Wilson)
- Ovarian Cancer Special Section
-
- 2 New Drug Pathways to EZH2 (Q Cao)
- Proton Beam Therapy (L Nogueira)
- Survivors Who Eat More Chicken and Less Meat (Y Wang)
- Men Who Have Obesity or Who Gain 10+ Pounds After Diagnosis (Y Wang)
- Prostatectomy for Black Men Who Also Have Obesity (A Vidal)
- Medicaid Alone Doesn't Improve Prostate Cancer Care (C Filson)
- 5 Years After Recommending Against Routine PSA Tests (A Jemal)
- Toxicity of Certain Immune Cells in Bone May Present New Treatment (L Cook)
- Heart Medicines May Spur Future Prostate Treatments (I Schlaepfer)
- Genetic Tool for Prostate Cancer in Blacks (K Yamoah)
- New Test May Predict Treatment for Prostate Cancer (R Blind)
- Untreatable Prostate Cancers (W Li)
-
- UV Exposure, Melanoma, & Dark Skin Types (A. Adamson)
- Melanoma and Lipid Droplets (R. White)
- Zebrafish and Acral Melanoma (R. White)
- T-Cell Lymphoma and PD1 (J. Choi)
- New Drug Destroys Cancer-Causing Protein (C. Crews)
- Virus & Merkel Cell Skin Cancer (R. Wang)
- Non-Genetic Drug Resistance (S. Spencer)
- Hijacking the Body's Sugar (R. Wang)
- Telling about High Risk (P. Kanetsky)
- Brain Metastasis and Alzheimer’s (E. Hernando)
- Exhausted Melanoma "Killer" Cells (W. Cui)
Discovery of a New Biomarker Is the First Step to New Treatment
An ACS grantee discovered a long non-coding RNA called RAMS11 that may help identify people with a high risk of metastatic colorectal cancer.
The Challenge
Approximately 50% of people with colorectal cancer (CRC) develop metastatic disease, meaning the cancer becomes advanced because it spreads from the colon to other places in the body, often to the liver or brain. While there are numerous ways to treat metastatic CRC, little is known about how to predict which treatment will work best for each patient. That lack of knowledge contributes to the low 5-year survival rate of 14% for this advanced type of CRC.
In order to develop more effective treatments, researchers need to better understand what drives CRC metastasis—how the original colorectal cancer (primary tumor) spreads. One thing they’re searching for are biological predictors (known as biomarkers) for metastasis.
The Research
Christopher Maher, PhD, and his lab team are looking for such biomarkers by studying molecules called long non-coding RNAs (lncRNAs). His lab collaborated with another ACS grantee, Ryan Fields, MD, who also works at Washington University School of Medicine.
“For decades, researchers focused on how genes that make proteins contribute to cancer. More recently, we identified a long non-coding RNA, which carries genetic code that doesn’t result in a protein, that has the potential to help doctors diagnosis and treat metastatic colon cancer. Our lab is dedicated to understanding how these RNAs contribute to metastatic colon cancer to help guide the development of new treatments for this most deadly stage of the disease.”–Christopher Maher, PhD
In colorectal cancer, IncRNAs have been shown to promote a tumor’s progression. Maher’s team recently published a study about the identification of a specific lncRNA in a CRC primary tumor that shows changes in metastatic tumors. This lncRNA is called RAMS11 (RAMS stands for RNAs Associated with MetastasiS).
They found RAMS11 at high levels in both primary CRC tumors and metastasized tumors, meaning it can possibly be used as a biomarker in certain cases to help diagnose metastatic CRC. This knowledge may help cancer doctors move from a one-size-fits-all treatment approach to a personalized and precision-based approach. It will help them more reliably predict which patients have the highest risk for developing metastatic cancer while allowing them to spare lower-risk patients from aggressive treatments.
Maher’s team also showed that RAMS11 triggers some tumors to metastasize and become resistant to some chemotherapy drugs.
Why It Matters
Maher’s identification of RAMS11 as a potential biomarker for CRC tumors that have metastasized is the first step toward the development of a new drug that could target RAMS11 to treat aggressive, metastatic forms of colorectal cancer.
Maher’s and Field’s work may also have a broader impact: they found high levels of RAMS11 in tumors for other types of cancer, and the chemotherapy drug they studied is also used for other cancer types.